Inhibition of CYP2C9 by natural products: insight into the potential risk of herb-drug interactions

References

• Achour B, Barber J, Rostami-Hodjegan A. 2014. Expression of hepatic drug-metabolizing cytochrome P450 enzymes and their inter-correlations: a meta-analysis. Drug Metab Dispos. 42(8):1349–1356.
   PubMed Web of Science ®Google Scholar
• Afilal D, Basselam MA, Brakez Z, Chouham S, Brehm A, Izaabel EH. 2017. Genetic polymorphism of drug-metabolism enzymes CYP2C9 and CYP2C19 in Moroccan population. Genet Test Mol Bioma. 21(5):298–304.
   PubMed Web of Science ®Google Scholar
• Almazroo OA, Miah MK, Venkataramanan R. 2017. Drug metabolism in the liver. Clin Liver Dis. 21(1):1–20.
   PubMed Web of Science ®Google Scholar
• Benjamin J, Muir T, Briggs K. 2001. A case of cerebral haemorrhage—can Ginkgo biloba be implicated? Postgrad Med J. 77(904):112–113.
   PubMed Web of Science ®Google Scholar
• Chatterjee P, Franklin MR. 2003. Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos. 31(11):1391–1397.
   PubMed Web of Science ®Google Scholar
• Chen A, Zhou X, Tang S, Liu M, Wang X. 2016. Evaluation of the inhibition potential of plumbagin against cytochrome P450 using LC-MS/MS and cocktail approach. Sci Rep. 6(1):28482.
   PubMed Web of Science ®Google Scholar
• Chen L, Yang H, Yu C, Yuan M, Li H. 2018. High hepatic exposure of furanocoumarins in Radix Angelica dahuricae is associated with transporter mediated active uptake. J Ethnopharmacol. 212:74–85.
   PubMed Web of Science ®Google Scholar
• Chen MN, Lin CC, Liu CF. 2015. Efficacy of phytoestrogens for menopausal symptoms: a meta-analysis and systematic review. Climacteric. 18(2):260–269.
   PubMed Web of Science ®Google Scholar
• Chen N, Yang X-Y, Guo C-E, Bi X-N, Chen J-H, Chen H-Y, Li H-P, Lin H-Y, Zhang Y-J. 2017. The oral bioavailability, excretion and cytochrome P450 inhibition properties of epiberberine: an in vivo and in vitro evaluation. Drug Des Devel Ther. 12:57–65.
   PubMed Web of Science ®Google Scholar
• Chen X, Dang TT, Facchini PJ. 2015. Noscapine comes of age. Phytochemistry. 111:7–13.
   PubMed Web of Science ®Google Scholar
• Chiangsom A, Lawanprasert S, Oda S, Kulthong K, Luechapudiporn R, Yokoi T, Maniratanachote R. 2016. Inhibitory and inductive effects of Phikud Navakot extract on human cytochrome P450. Drug Metab Pharmacokinet. 31(3):210–217.
   PubMed Web of Science ®Google Scholar
• Choi DH, Li C, Choi JS. 2010. Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin. J Pharm Pharmacol. 62(7):908–914.
   PubMed Web of Science ®Google Scholar
• Cieniak C, Liu R, Fottinger A, Smiley SAM, Guerrero-Analco JA, Bennett SAL, Haddad PS, Cuerrier A, Saleem A, Arnason JT, et al. 2013. In vitro inhibition of metabolism but not transport of gliclazide and repaglinide by Cree medicinal plant extracts. J Ethnopharmacol. 150(3):1087–1095.
   PubMed Web of Science ®Google Scholar
• Dickmann LJ, VandenBrink BM, Lin YS. 2012. In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosicacid, a dietary supplement with antiadipogenic properties. Drug Metab Dispos. 40(7):1263–1267.
   PubMed Web of Science ®Google Scholar
• Ding T, Zhang Y, Chen A, Tang Y, Liu M, Wang X. 2015. Effects of cucurbitacin E, a tetracyclic triterpene compound from Cucurbitaceae, on the pharmacokinetics and pharmacodynamics of warfarin in rats. Basic Clin Pharmacol Toxicol. 116(5):385–389.
   PubMed Web of Science ®Google Scholar
• Donovan JL, DeVane CL, Chavin KD, Taylor RM, Markowitz JS. 2003. Siberian ginseng (Eleutheroccus senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers. Drug Metab Dispos. 31(5):519–522.
   PubMed Web of Science ®Google Scholar
• Etheridge A, Black S, Patel P, So J, Mathews J. 2007. An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med. 73(8):731–741.
   PubMed Web of Science ®Google Scholar
• Fang Z-Z, Zhang Y-Y, Ge G-B, Huo H, Liang S-C, Yang L. 2010. Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine–warfarin interaction. Br J Clin Pharmacol. 69(2):193–199.
   PubMed Web of Science ®Google Scholar
• Flora DR, Rettie AE, Brundage RC, Tracy TS. 2017. CYP2C9 genotype-dependent warfarin pharmacokinetics: impact of CYP2C9 genotype on R- And S-warfarin and their oxidative metabolites. J Clin Pharmacol. 57(3):382–393.
   PubMed Web of Science ®Google Scholar
• Foti RS, Pearson JT, Rock DA, Wahlstrom JL, Wienkers LC. 2009. In vitro inhibition of multiple cytochrome P450 isoforms by xanthone derivatives from Mangosteen extract. Drug Metab Dispos. 37(9):1848–1855.
   PubMed Web of Science ®Google Scholar
• Gaudineau C, Beckerman R, Welbourn S, Auclair K. 2004. Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochem Bioph Res Co. 318(4):1072–1078.
   PubMed Web of Science ®Google Scholar
• Girennavar B, Jayaprakasha GK, Patil BS. 2007. Potent inhibition of human cytochrome P450 3A4, 2D6, and 2C9 isoenzymes by grapefruit juice and its furocoumarins. J Food Science. 72(8):C417–421.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, von Moltke LL. 2005. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol. 45(2):127–132.
   PubMed Web of Science ®Google Scholar
• Guengerich FP, Waterman MR, Egli M. 2016. Recent structural insights into cytochrome P450 function. Trends Pharmacol Sci. 37(8):625–640.
   PubMed Web of Science ®Google Scholar
• Guo LQ, Yamazoe Y. 2004. Inhibition of cytochrom P450 by furanocoumarins in grapefruit juice and herbal medicines. Acta Pharmacol Sin. 25(2):129–136.
   PubMed Web of Science ®Google Scholar
• Guo Y, Chen Y, Tan Z-r, Klaassen CD, Zhou H-h. 2012. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 68(2):213–217.
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CYW. 2005. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John’s wort, garlic oil, panax ginseng and ginkgo biloba. Drugs Aging. 22(6):525–539.
   PubMed Web of Science ®Google Scholar
• Hao X, Yuan J, Xu Y, Wang Z, Hou J, Hu T. 2018. In vitro inhibitory effects of pristimerin on human liver cytochrome P450 enzymes. Xenobiotica. 48(12):1185–1191.
   PubMed Web of Science ®Google Scholar
• He N, Edeki T. 2004. The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am J Ther. 11(3):206–212.
   PubMedGoogle Scholar
• Hermann R, von Richter O. 2012. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med. 78(13):1458–1477.
   PubMed Web of Science ®Google Scholar
• Hu Z, Yang X, Ho PCL, Chan SY, Heng PWS, Chan E, Duan W, Koh HL, Zhou S. 2005. Herb-drug interactions: a literature review. Drugs. 65(9):1239–1282.
   PubMed Web of Science ®Google Scholar
• Hung WL, Suh JH, Wang Y. 2017. Chemistry and health effects of furanocoumarins in grapefruit. J Food Drug Anal. 25(1):71–83.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M, Oscarson M, Mclellan RA. 1999. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci. 20(8):342–349.
   PubMed Web of Science ®Google Scholar
• Jeong H-U, Kong T, Kwon S, Hong S-W, Yeon S, Choi J-H, Lee J, Cho Y, Lee H. 2013. Effect of honokiol on cytochrome P450 and UDP-Glucuronosyltransferase enzyme activities in human liver microsomes. Molecules. 18(9):10681–10693.
   PubMed Web of Science ®Google Scholar
• Jeong H-U, Kwon S-S, Kong TY, Kim JH, Lee HS. 2014. Inhibitory effects of cedrol, β-cedrene, and thujopsene on cytochrome P450 enzyme activities in human liver microsomes. J Toxicol Environ Health A. 77(22–24):1522–1532.
   PubMed Web of Science ®Google Scholar
• Ji HY, Kim SY, Kim DK, Jeong JH, Lee HS. 2010. Effects of eupatilin and jaceosidin on cytochrome P450 enzyme activities in human liver microsomes. Molecules. 15(9):6466–6475.
   PubMed Web of Science ®Google Scholar
• Ji X, Avula B, Khan IA. 2007. Quantitative and qualitative determination of six xanthones in Garcinia mangostana L. by LC-PDA and LC-ESI-MS. J Pharm Biomed Anal. 43(4):1270–1276.
   PubMed Web of Science ®Google Scholar
• Jiang Q-q, Fan L-y, Yang G-l, Guo W-H, Hou W-l, Chen L-j, Wei Y-q. 2008. Improved therapeutic effectiveness by combining liposomal honokiol with cisplatin in lung cancer model. BMC Cancer. 8(1):242.
   PubMed Web of Science ®Google Scholar
• Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. 2004. Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol. 57(5):592–599.
   PubMed Web of Science ®Google Scholar
• Joo J, Lee D, Wu Z, Shin J-H, Lee HS, Kwon B-M, Huh T-L, Kim Y-W, Lee S-J, Kim TW, et al. 2013. In vitro metabolism of obovatol and its effect on cytochrome P450 enzyme activities in humanliver microsomes. Biopharm Drug Dispos. 34(4):195–202.
   PubMed Web of Science ®Google Scholar
• Kim IS, Kim Y, Kwak TH, Yoo HH. 2013. Effects of β-lapachone, a new anticancer candidate, on cytochrome P450-mediated drug metabolism. Cancer Chemother Pharmacol. 72(3):699–702.
   PubMed Web of Science ®Google Scholar
• Kim J-Y, Lee SY, Kim D-H, Kim B-R, Park R, Lee BM. 2002. Effects of flavonoids isolated from Scutellariae radix on cytochrome P-450 activities in human liver microsomes. J Toxicol Environ Health A. 65(5-6):373–381.
   PubMed Web of Science ®Google Scholar
• Kimura Y, Ito H, Ohnishi R, Hatano T. 2010. Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity. Food Chem Toxicol. 48(1):429–435.
   PubMed Web of Science ®Google Scholar
• Korobkova EA. 2015. Effect of natural polyphenols on CYP metabolism: implications for diseases. Chem Res Toxicol. 28(7):1359–1390.
   PubMed Web of Science ®Google Scholar
• Iyer L. 1999. Inherited variations in drug-metabolizing enzymes: significance in clinical oncology. Mol Diag. 4(4):327–333.
   PubMedGoogle Scholar
• Lam AY, Elmer GW, Mohutsky MA. 2001. Possible interaction between warfarin and Lycium barbarum L. Ann Pharmacother. 35(10):1199–1201.
   PubMed Web of Science ®Google Scholar
• Lee CR, Goldstein JA, Pieper JA. 2002. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 12(3):251–263.
   PubMedGoogle Scholar
• Li H, Liu L, Xie L, Gan D, Jiang X. 2016. Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. Pharm Biol. 54(12):2886–2894.
   PubMed Web of Science ®Google Scholar
• Lin G, Tang J, Liu XQ, Jiang Y, Zheng J. 2007. Deacetylclivorine: a gender-selective metabolite of clivorine formed in female Sprague-Dawley rat liver microsomes. Drug Metab Dispos. 35(4):607–613.
   PubMed Web of Science ®Google Scholar
• Lin JH, Lu AY. 2001. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol. 41(1):535–567.
   PubMed Web of Science ®Google Scholar
• Liu R, Tam TW, Mao J. 2016. In vitro activity of Lycium barbarum (Goji) against major human phase I metabolism enzymes. J Complement Integr Med. 13(3):257–265.
   PubMedGoogle Scholar
• Lou D, Bao S-S, Li Y-H, Lin Q-M, Yang S-F, He J-Y. 2019. Inhibitory mechanisms of myricetin on human and rat liver cytochrome P450 enzymes. Eur J Drug Metab Pharmacokinet. 44(5):611–618.
   PubMed Web of Science ®Google Scholar
• Lu J, Ding T, Qin X, Liu M, Wang X. 2017. In vitro and in vivo evaluation of cucurbitacin E on rat hepatic CYP2C11 expression and activity using LC-MS/MS. Sci China Life Sci. 60(2):215–224.
   PubMed Web of Science ®Google Scholar
• Mafuvadze B, Cook M, Xu Z, Besch-Williford CL, Hyder SM. 2013. Effects of dietary apigenin on tumor latency, incidence and multiplicity in a medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced breast cancer model. Nutr Cancer. 65(8):1184–1191.
   PubMed Web of Science ®Google Scholar
• Maggioni D, Garavello W, Rigolio R, Pignataro L, Gaini R, Nicolini G. 2013. Apigenin impairs oral squamous cell carcinoma growth in vitro inducing cell cycle arrest and apoptosis. Int J Oncol. 43(5):1675–1682.
   PubMed Web of Science ®Google Scholar
• Mao X, Peng Y, Zheng J. 2015. In Vitro and In Vivo characterization of reactive intermediates of corynoline. Drug Metab Dispos. 43(10):1491–1498.
   PubMed Web of Science ®Google Scholar
• Mao X, Zhao H, Wang Q, Li H, Yang L, Hu Z, Zhang F, Guo X, Peng Y, Zheng J, et al. 2019. Metabolism-based herb-drug interaction of Corydalis Bungeanae Herba with berberine in vitro and in vivo in rats. Biomed Chromatogr. 33(7):e4514.
   PubMed Web of Science ®Google Scholar
• Manda VK, Dale OR, Awortwe C, Ali Z, Khan IA, Walker LA, Khan SI. 2014. Evaluation of drug interaction potential of Labisia pumila (Kacip Fatimah) and its constituents. Front Pharmacol. 5:178
   PubMed Web of Science ®Google Scholar
• Mathews JM, Etheridge AS, Black SR. 2002. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab Dispos. 30(11):1153–1157.
   PubMed Web of Science ®Google Scholar
• Matthews MK. 1998. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology. 50(6):1933–1934.
   PubMed Web of Science ®Google Scholar
• Michler H, Laakmann G, Wagner H. 2011. Development of an LC-MS method for simultaneous quantitation of amentoflavone and biapigenin, the minor and major biflavones from Hypericum perforatum L., in human plasma and its application to real blood. Phytochem Anal. 22(1):42–50.
   PubMed Web of Science ®Google Scholar
• Misaka S, Abe O, Sato H, Ono T, Shikama Y, Onoue S, Yabe H, Kimura J. 2018. Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers. Eur J Clin Pharmacol. 74(5):601–609.
   PubMed Web of Science ®Google Scholar
• Mohutsky MA, Anderson GD, Miller JW, et al. 2006. Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. Am J of Ther. 13:24–31.
   PubMed Web of Science ®Google Scholar
• Mooiman KD, Goey AKL, Huijbregts TJ, Maas-Bakker RF, Beijnen JH, Schellens JHM, Meijerman I. 2014. The in vitro effect of complementary and alternative medicines on cytochrome P450 2C9 activity. J Pharm Pharmacol. 66(9):1339–1346.
   PubMed Web of Science ®Google Scholar
• Niinuma Y, Saito T, Takahashi M, Tsukada C, Ito M, Hirasawa N, Hiratsuka M. 2014. Functional characterization of 32 CYP2C9 allelic variants. Pharmacogenomics J. 14(2):107–114.
   PubMed Web of Science ®Google Scholar
• Numa AM, Abbott FS, Chang T. 2007. Effect of Ginkgo biloba extract on oxidative metabolism of valproic acid in hepatic microsomes from donors with the CYP2C9*1/*1 genotype. Can J Physiol Pharmacol. 85(9):848–855.
   PubMed Web of Science ®Google Scholar
• Obach RS. 2000. Inhibition of human cytochrome P450 enzymes by constituents of St. John’s Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther. 294(1):88–95.
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K. 2007. Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos. 35(2):246–255.
   PubMed Web of Science ®Google Scholar
• Ohlsson S, Holm L, Myrberg O, Sundström A, Yue Q-Y. 2008. Noscapine may increase the effect of warfarin. Br J Clin Pharmacol. 65(2):277–278.
   PubMed Web of Science ®Google Scholar
• Pan Y, Abd-Rashid BA, Ismail Z, Ismail R, Mak JW, Pook PCK, Er HM, Ong CE. 2010. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica. J Ethnopharmacol. 130 (2):275–283.
   PubMed Web of Science ®Google Scholar
• Pan Y, Abd-Rashid BA, Ismail Z, Ismail R, Mak JW, Pook PCK, Er HM, Ong CE. 2011. In vitro determination of the effect of Andrographis paniculate extracts and andrographolide on human hepatic cytochrome P450 activities. J Nat Med. 65(3-4):440–447.
   PubMed Web of Science ®Google Scholar
• Petiwala SM, Li G, Ramaiya A, Kumar A, Gill RK, Saksena S, Johnson JJ. 2014. Pharmacokinetic characterization of mangosteen (Garcinia mangostana) fruit extract standardized to α-mangostin in C57BL/6 mice. Nutr Res. 34(4):336–345.
   PubMed Web of Science ®Google Scholar
• Qian P, Zhang Y-B, Yang Y-F, Xu W, Yang X-W. 2017. Pharmacokinetics studies of 12 alkaloids in rat plasma after oral administration of Zuojin and Fan-Zuojin formulas. Molecules. 22(2):214.
   PubMed Web of Science ®Google Scholar
• Qin L, Xue M, Wang W, Zhu R, Wang S, Sun J, Zhang R, Sun X. 2010. The in vitro and in vivo anti-tumor effect of layered double hydroxides nanoparticles as delivery for podophyllotoxin. Int J Pharm. 388(1-2):223–230.
   PubMed Web of Science ®Google Scholar
• Ramasamy S, Kiew LV, Chung LY. 2014. Inhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents. Molecules. 19(2):2588–2601.
   PubMed Web of Science ®Google Scholar
• Rendic S. 2002. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 34(1–2):83–448.
   PubMed Web of Science ®Google Scholar
• Rendic S, Di Carlo FJ. 1997. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev. 29(1-2):413–580.
   PubMed Web of Science ®Google Scholar
• Rendic S, Guengerich FP. 2015. Survey of human oxidoreductases and cytochrome P450 enzymes involved in the metabolism of xenobiotic and natural chemicals. Chem Res Toxicol. 28(1):38–42.
   PubMed Web of Science ®Google Scholar
• Rosenborg S, Stenberg M, Otto S, Östervall J, Masquelier M, Yue Q-Y, Bertilsson L, Eliasson E. 2010. Clinically significant CYP2C inhibition by noscapine but not by glucosamine. Clin Pharmacol Ther. 88(3):343–346.
   PubMed Web of Science ®Google Scholar
• Row E, Brown SA, Stachulski AV, Lennard MS. 2006. Development of novel furanocoumarin dimers as potent and selective inhibitors of CYP3A4. Drug Metab Dispos. 34(2):324–330.
   PubMed Web of Science ®Google Scholar
• Sahu R, Ahmed T, Sangana R, Punde R, Subudhi BB. 2018. Effect of Tinospora cordifolia aqua-alcoholic extract on pharmacokinetic of Glibenclamide in rat: an herb-drug interaction study. J Pharm Biomed Anal. 151:310–316.
   PubMed Web of Science ®Google Scholar
• Satoh T, Fujisawa H, Nakamura A, Takahashi N, Watanabe K. 2016. Inhibitory effects of eight green tea catechins on cytochrome P450 1A2, 2C9, 2D6, and 3A4 activities. J Pharm Pharm Sci. 19(2):188–197.
   PubMed Web of Science ®Google Scholar
• Scordo MG, Melhus H, Stjernberg E, Edvardsson AM, Wadelius M. 2008. Warfarin–noscapine interaction: a series of four case reports. Ann Pharmacother. 42(3):448–455.
   PubMed Web of Science ®Google Scholar
• Shamsi S, Tran H, Tan RSJ, Tan ZJ, Lim LY. 2017. Curcumin, piperine, and capsaicin: a comparative study of spice-mediated inhibition of human cytochrome P450 isozyme activities. Drug Metab Dispos. 45(1):49–55.
   PubMed Web of Science ®Google Scholar
• Shi X, Yang S, Zhang G, Song Y, Su D, Liu Y, Guo F, Shan L, Cai J. 2016. The different metabolism of morusin in various species and its potent inhibition against UDP-glucuronosyltransferase (UGT) and cytochrome p450 (CYP450) enzymes. Xenobiotica. 46(5):467–476.
   PubMed Web of Science ®Google Scholar
• Shi X, Zhang G, Ge G, Guo Z, Song Y, Su D, Shan L. 2019. In vitro metabolism of auriculasin and its inhibitory effects on human cytochrome P450 and UDP-glucuronosyltransferase enzymes. Chem Res Toxicol. 32(10):2125–2134.
   PubMed Web of Science ®Google Scholar
• Si D, Wang Y, Zhou Y-H, Guo Y, Wang J, Zhou H, Li Z-S, Fawcett JP. 2009. Mechanism of CYP2C9 inhibition by flavones and flavonols. Drug Metab Dispos. 37(3):629–634.
   PubMed Web of Science ®Google Scholar
• Song J-H, Sun D-X, Chen B, Ji D-H, Pu J, Xu J, Tian F-D, Guo L. 2011. Inhibition of CYP3A4 and CYP2C9 by podophyllotoxin implication for clinical drug-druginteractions. J Biosci. 36(5):879–885.
   PubMed Web of Science ®Google Scholar
• Sorensen JM. 2002. Herb–drug, food–drug, nutrient–drug, and drug–drug interactions: mechanisms involved and their medical implications. J Altern Compl Med. 8:293–308.
   PubMed Web of Science ®Google Scholar
• Tan BH, Ahemad N, Pan Y, Palanisamy UD, Othman I, Yiap BC, Ong CE. 2018. Cytochrome P450 2C9-natural antiarthritic interactions: evaluation of inhibition magnitude and prediction from in vitro data. Biopharm Drug Dispos. 39(4):205–217.
   PubMed Web of Science ®Google Scholar
• Tang J-c, Yang H, Song X-y, Song X-h, Yan S-l, Shao J-q, Zhang T-l, Zhang J-n. 2009. Inhibition of cytochrome P450 enzymes by rhein in rat liver microsomes. Phytother Res. 23(2):159–164.
   PubMed Web of Science ®Google Scholar
• Tang S, Chen A, Zhou X, Zeng L, Liu M, Wang X. 2017. Assessment of the inhibition risk of shikonin on cytochrome P450 via cocktail inhibition assay. Toxicol Lett. 281:74–83.
   PubMed Web of Science ®Google Scholar
• Tassaneeyakul W, Guo L-Q, Fukuda K, Ohta T, Yamazoe Y. 2000. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch Biochem Biophys. 378(2):356–363.
   PubMed Web of Science ®Google Scholar
• Thomford NE, Mkhize B, Dzobo K, Mpye K, Rowe A, Parker MI, Wonkam A, Skelton M, September AV, Dandara C. 2016. African Lettuce (Launaea taraxacifolia) displays possible anticancer effects and herb-drug interaction potential by CYP1A2, CYP2C9, and CYP2C19 inhibition. Omics. 20(9):528–537.
   PubMed Web of Science ®Google Scholar
• Thu OKF, Spigset O, Hellum B. 2017. Noncompetitive inhibition of human CYP2C9 in vitro bya commercial Rhodiola rosea product. Pharmacol Res Perspect. 5(4):e00324.
   PubMed Web of Science ®Google Scholar
• Ueng Y-F, Chen C-C, Yamazaki H, Kiyotani K, Chang Y-P, Lo W-S, Li D-T, Tsai P-L. 2013. Mechanism-based inhibition of CYP1A1 and CYP3A4 by the furanocoumarin chalepensin. Drug Metab Pharmacokinet. 28 (3):229–238.
   PubMed Web of Science ®Google Scholar
• Valli G, Giardina AV. 2002. Benefits, adverse effects and drug interactions of herbal therapies with cardiovascular effects. J Am Coll Cardiol. 39(7):1083–1095.
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Weemhoff JL, Bedir E, Khan IA, Harmatz JS, Goldman P, Greenblatt DJ. 2004. Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol. 56(8):1039–1044.
   PubMed Web of Science ®Google Scholar
• Wang B, Wang J, Huang S-Q, Su H-H, Zhou S-F. 2009. Genetic polymorphism of the human cytochrome P450 gene and its clinical significance. CDM. 10(7):781–834.
   Web of Science ®Google Scholar
• Wang H, Wang K, Mao X, Zhang Q, Yao T, Peng Y, Zheng J. 2015. Mechanism-based inactivation of CYP2C9 by linderane. Xenobiotica. 45(12):1037–1046.
   PubMed Web of Science ®Google Scholar
• Wang R, Zhang H, Wang Y, Yu X, Yuan Y. 2016. Effects of salvianolic acid B and tanshinone IIA on the pharmacokinetics of losartan in rats by regulating the activities and expression of CYP3A4 and CYP2C9. J Ethnopharmacol. 180:87–96.
   PubMed Web of Science ®Google Scholar
• Wang X, Cheung CM, Lee WYW, Or PMY, Yeung JHK. 2010. Major tanshinones of Danshen (Salvia miltiorrhiza) exhibit different modes of inhibition on human CYP1A2, CYP2C9, CYP2E1 and CYP3A4 activities in vitro. Phytomedicine. 17(11):868–875.
   PubMed Web of Science ®Google Scholar
• Wang X, Duan X, Yang G, Zhang X, Deng L, Zheng H, Deng C, Wen J, Wang N, Peng C, et al. 2011. Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. Plos One. 6(4):e18490.
   PubMed Web of Science ®Google Scholar
• Wang X, Lee WYW, Or PMY, Yeung JHK. 2010. Pharmacokinetic interaction studies of tanshinones with tolbutamide, a model CYP2C11 probe substrate, using liver microsomes, primary hepatocytes and in vivo in the rat. Phytomedicine. 17(3-4):203–211.
   PubMed Web of Science ®Google Scholar
• Wang Z, Gong Y, Zeng D-l, Chen L-g, Lin G-t, Huang C-k, Sun W, Chen M-C, Hu G-x, Chen R-j. 2016. Inhibitory effect of apigenin on losartan metabolism and CYP2C9 activity in vitro. Pharmacology. 98(3-4):183–189.
   PubMed Web of Science ®Google Scholar
• Wienkers LC, Heath TG. 2005. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov. 4 (10):825–833.
   PubMed Web of Science ®Google Scholar
• Wu YJ, Chen JJ, Cheng YY. 2005. A sensitive and specific HPLC-MS method for the determination of sophoridine, sophocarpineand matrine in rabbit plasma. Anal Bioanal Chem. 382(7):1595–1600.
   PubMed Web of Science ®Google Scholar
• Ye L-H, Zhao X-Q, Kong L-T, Wang L-S, Tao X, Wu H, He M, Chang Q. 2018. Inhibitory effects of Danhong injection and its major constituents on human cytochrome P450 enzymes in vitro. Biomed Chromatogr. 32(8):e4250.
   PubMed Web of Science ®Google Scholar
• Yoon M-S, Lee JS, Choi B-M, Jeong Y-I, Lee C-M, Park J-H, Moon Y, Sung S-C, Lee SK, Chang YH, et al. 2006. Apigenin inhibits immunostimulatory function of dendritic cells: implication of immunotherapeutic adjuvant. Mol Pharmacol. 70(3):1033–1044.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Qiu X, Nikolić D, Chen S-N, Huang K, Li G, Pauli GF, van Breemen RB. 2014. Inhibition of human cytochrome P450 enzymes by hops (Humulus lupulus) and hop prenylphenols. Eur J Pharm Sci. 53:55–61.
   PubMed Web of Science ®Google Scholar
• Zhang F-L, He X, Zhai Y-R, He L-N, Zhang S-C, Wang L-L, Yang A-H, An L-J. 2015. Mechanism-based inhibition of CYPs and RMs-induced hepatoxicity by rutaecarpine. Xenobiotica. 45(11):978–989.
   PubMed Web of Science ®Google Scholar
• Zhang J, Li C, Zhang J, Zhang F. 2019. In vitro inhibitory effects of sophocarpine on human liver cytochrome P450 enzymes. Xenobiotica. 49(10):1127–1132.
   Google Scholar
• Zhang J, Tian L, Xie B. 2015. Bleeding due to a probable interaction between Warfarin and Gouqizi (Lycium Barbarum L.). Toxicol Rep. 2:1209–1212.
   PubMed Web of Science ®Google Scholar
• Zhang N, Seguin RP, Kunze KL, Zhang Y-Y, Jeong H. 2013. Characterization of inhibition kinetics of (S)-warfarin hydroxylation by noscapine: implications in warfarin therapy. Drug Metab Dispos. 41(12):2114–2123.
   PubMed Web of Science ®Google Scholar
• Zhang ZY, Wong YN. 2005. Enzyme kinetics for clinically relevant CYP inhibition. Curr Drug Metab. 6(3):241–257.
   PubMed Web of Science ®Google Scholar
• Zheng YF, Bae SH, Choi EJ, Park JB, Kim SO, Jang MJ, Park GH, Shin WG, Oh E, Bae SK. 2014. Evaluation of the in vitro/in vivo drug interaction potential of BST204, a purified dry extract of ginseng, and its four bioactive ginsenosides through cytochrome P450 inhibition/induction and UDP-glucuronosyltransferase inhibition. Food Chem Toxicol. 68:117–127.
   PubMed Web of Science ®Google Scholar
• Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL. 2005. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 44(3):279–304.
   PubMed Web of Science ®Google Scholar
• Zhou S-F, Zhou Z-W, Yang L-P, Cai J-P. 2009. Substrates, inducers, inhibitors and structure-activity relationships of human cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 16(27):3480–3675.
   PubMed Web of Science ®Google Scholar
• Zhuang Q, Pan R, Liu X, Xu W, Wang H, Zhang X, Lai X, Wang H, Zhang L, Jiang J. 2019. A validated ultra-HPLC–MS/MS method for determination of honokiol in human plasma and its application to a clinical pharmacokinetic study. Bioanalysis. 11(11):1085–1098.
   PubMed Web of Science ®Google Scholar